Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis
- PMID: 9781472
- DOI: 10.1023/a:1022349920283
Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis
Abstract
Tardive dyskinesia is an involuntary movement disorder developing following treatment with neuroleptics. As many as 50% of chronic psychotic patients develop this disabling condition. No treatment has been found effective for tardive dyskinesia. This study was undertaken to meta-analyze the effects of vitamin E (alpha-tocopherol) reported in the last decade. All studies published since 1987, focusing on vitamin E and tardive dyskinesia are reviewed. Double-blind studies are analyzed using measures of effect and variance as described by secondary analysis of magnitude of effects in pooled data. A total of 223 patients received vitamin E treatment (400-1600 IU/day) for tardive dyskinesia, in 12 studies. A significant subgroup (28.3%) showed a modest improvement. Vitamin E was well tolerated, and only rarely did side effects occur-of no clinical significance. Vitamin E is a safe, well-tolerated compound that may provide some beneficial effects in patients suffering from neuroleptic-induced tardive dyskinesia.
Similar articles
-
Oxidative mechanisms and tardive dyskinesia.CNS Drugs. 2003;17(1):47-62. doi: 10.2165/00023210-200317010-00004. CNS Drugs. 2003. PMID: 12467492 Review.
-
Treatment of tardive dyskinesia with vitamin E.Am J Psychiatry. 1992 Jun;149(6):773-7. doi: 10.1176/ajp.149.6.773. Am J Psychiatry. 1992. PMID: 1350428 Clinical Trial.
-
Vitamin E treatment of tardive dyskinesia.Am J Psychiatry. 1993 Sep;150(9):1405-7. doi: 10.1176/ajp.150.9.1405. Am J Psychiatry. 1993. PMID: 8102511 Clinical Trial.
-
Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.Arch Gen Psychiatry. 1999 Sep;56(9):836-41. doi: 10.1001/archpsyc.56.9.836. Arch Gen Psychiatry. 1999. PMID: 12892048 Clinical Trial.
-
Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2.Ann Pharmacother. 2005 Dec;39(12):2065-72. doi: 10.1345/aph.1G271. Epub 2005 Nov 15. Ann Pharmacother. 2005. PMID: 16288072 Review.
Cited by
-
Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting.Cell Mol Neurobiol. 2001 Dec;21(6):605-16. doi: 10.1023/a:1015187601628. Cell Mol Neurobiol. 2001. PMID: 12043836 Free PMC article. Review.
-
Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.Psychopharmacology (Berl). 2005 Aug;181(1):71-9. doi: 10.1007/s00213-005-2222-6. Epub 2005 Oct 15. Psychopharmacology (Berl). 2005. PMID: 15806417
-
Oxidative mechanisms and tardive dyskinesia.CNS Drugs. 2003;17(1):47-62. doi: 10.2165/00023210-200317010-00004. CNS Drugs. 2003. PMID: 12467492 Review.
-
Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders.CNS Drugs. 2004;18(12):807-25. doi: 10.2165/00023210-200418120-00005. CNS Drugs. 2004. PMID: 15377170 Review.
-
Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.Drugs Aging. 2000 Nov;17(5):363-84. doi: 10.2165/00002512-200017050-00004. Drugs Aging. 2000. PMID: 11190417 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials